glp 1 medication shortage FDA's compounded GLP-1 limits will have ripple effects throughout the retail industry Chart: 1 in 8 Americans

31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria

GLP-1 T from True Form Peptides features 99% purity and HPLC verification

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

Benefits: Helps reduce stubborn fat, supports cardiovascular and immune health, promotes digestion, and contributes to long-term metabolic and weight management

Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.